Cassie Jung Biography and Net Worth

Cassie Jung joined Aquestive in 2004 and since then, has held leadership positions across various areas of the business including Quality Assurance, Alliance Management, Clinical Operations, and Portfolio Management. Ms. Jung was instrumental in the execution of Aquestive’s internal CNS development pipeline and in 2019, was appointed Vice President Operations, responsible for all facets of the company’s manufacturing operations.

Ms. Jung is currently the Chief Operating Officer and oversees several key functions across the company, including manufacturing operations, product management, and corporate communications. Ms. Jung received her B.S. in Management from Purdue University.

What is Cassie Jung's net worth?: The estimated net worth of Cassie Jung is at least $1.55 million as of October 15th, 2025. Ms. Jung owns 240,771 shares of Aquestive Therapeutics stock worth more than $1,550,565 as of December 5th. This net worth evaluation does not reflect any other investments that Ms. Jung may own. Learn More about Cassie Jung's net worth.
How old is Cassie Jung?: Ms. Jung is currently 44 years old. There are 8 older executives and no younger executives at Aquestive Therapeutics. The oldest executive at Aquestive Therapeutics is Ms. Lori J. Braender BSBA, Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary, who is 68 years old. Learn More on Cassie Jung's age.
How do I contact Cassie Jung?: The corporate mailing address for Ms. Jung and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Cassie Jung's contact information.
Has Cassie Jung been buying or selling shares of Aquestive Therapeutics?: During the last quarter, Cassie Jung has sold $473,700.75 in shares of Aquestive Therapeutics stock. Most recently, Cassie Jung sold 67,575 shares of the business's stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $7.01, for a transaction totalling $473,700.75. Following the completion of the sale, the chief operating officer now directly owns 240,771 shares of the company's stock, valued at $1,687,804.71. Learn More on Cassie Jung's trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Cassie Jung (COO), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 8 times. They sold a total of 276,770 shares worth more than $1,692,203.04. The most recent insider tranaction occured on October, 15th when COO Cassie Jung sold 67,575 shares worth more than $473,700.75. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 10/15/2025.

Cassie Jung Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/15/2025	Sell	67,575	$7.01	$473,700.75	240,771
9/4/2025	Sell	62,180	$5.00	$310,900.00	283,346
11/26/2024	Sell	44	$4.87	$214.28	233,066

Cassie Jung Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $6.44

$6.13

$6.55

50 Day Range

MA: $6.25

$5.30

$7.49

2 Week Range

Now: $6.44

$2.12

$7.55

Volume

2,274,110 shs

Average Volume

2,709,055 shs

Market Capitalization

$785.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Cassie Jung Biography and Net Worth

What is Cassie Jung's net worth?

How old is Cassie Jung?

How do I contact Cassie Jung?

Has Cassie Jung been buying or selling shares of Aquestive Therapeutics?

Who are Aquestive Therapeutics' active insiders?

Are insiders buying or selling shares of Aquestive Therapeutics?